Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes, R C Bliss, J M Espie, M Erdkamp, F Wals, J Tres, A Marty, M Coleman, R E Tubiana-Mathieu, N den Boer, M O
Coombes, R C
Bliss, J M
Espie, M
Erdkamp, F
Wals, J
Tres, A
Marty, M
Coleman, R E
Tubiana-Mathieu, N
den Boer, M O
Citations
Altmetric:
Abstract
The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer.
Description
Date
2011-08-20
Publisher
Collections
Keywords
Type
Article
Citation
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. 2011, 29 (24):3247-54 J. Clin. Oncol.